Scholarlink

Purpose <p>Assess real-world efficacy and safety of intravitreal faricimab in the management of central serous chorioretinopathy (CSCR) associated choroidal neovascularization (CNV).</p> Methods <p>In this multicenter retrospective study, Patients receiving one or more intravitreal faricimab injections for CSCR-associated CNV were included. Subgroup analysis involved both treatment-naïve individuals and those switched from prior anti-VEGF agents. Clinical and anatomical parameters including best-recorded visual acuity (BRVA), central macular thickness (CMT), subfoveal choroidal thickness (SFCT), neurosensory detachment (NSD), and pigment epithelial detachment (PED) height—were assessed at baseline and at one month after the first and third injections. Treatment response was categorized as complete resolution (absence of subretinal fluid [SRF]/intraretinal fluid [IRF]), optimal (&gt; 50% SRF reduction or subjective IRF improvement), or suboptimal(no improvement/worsening) response.</p> Results <p>A total of 42 eyes (40 patients) across six centers were included. Mean age was 62.38 ± 9.48 years and 62.5% were males. Nineteen eyes were treatment-naïve, while 23 had received prior anti-VEGF therapy. Mean BCVA improved significantly from 0.78 ± 0.41 to 0.59 ± 0.35 logMAR after the first dose (<i>p</i> &lt; 0.001), and from 0.71 ± 0.43 to 0.59 ± 0.57 logMAR following the third dose (<i>p</i> = 0.011). Significant reductions in CMT, SFCT, and NSD height were observed post-treatment; however, PED height did not change significantly. Similar results were seen in both subgroups after the first injection. Complete SRF resolution was achieved in 43% of eyes, with 45.7% showing optimal and 11.4% suboptimal response. One patient developed bilateral anterior uveitis after the third injection, which resolved with topical corticosteroids.</p> Conclusion <p>Intravitreal faricimab appears to be a safe and effective option for CSCR-associated CNV, demonstrating anatomical and functional improvements, particularly in cases with unresponsive to prior anti-VEGFs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of intravitreal faricimab for choroidal neovascularization secondary to central serous chorioretinopathy – a multicentre study

  • 期刊论文

  • 发表日期：

    2025年11月8日

查看全文
  • Nasiq Hasan,
  • Elham Sadeghi,
  • Luiz H. Lima,
  • Jay C. Wang,
  • Rahul N. Khurana,
  • Avery Zhou,
  • Charles C. Wykoff,
  • David Eichenbaum,
  • Lihteh Wu,
  • Alexander J. Anetakis,
  • Andrew W. Eller,
  • Jose A. Sahel,
  • Jay Chhablani

摘要

Purpose

Assess real-world efficacy and safety of intravitreal faricimab in the management of central serous chorioretinopathy (CSCR) associated choroidal neovascularization (CNV).

Methods

In this multicenter retrospective study, Patients receiving one or more intravitreal faricimab injections for CSCR-associated CNV were included. Subgroup analysis involved both treatment-naïve individuals and those switched from prior anti-VEGF agents. Clinical and anatomical parameters including best-recorded visual acuity (BRVA), central macular thickness (CMT), subfoveal choroidal thickness (SFCT), neurosensory detachment (NSD), and pigment epithelial detachment (PED) height—were assessed at baseline and at one month after the first and third injections. Treatment response was categorized as complete resolution (absence of subretinal fluid [SRF]/intraretinal fluid [IRF]), optimal (> 50% SRF reduction or subjective IRF improvement), or suboptimal(no improvement/worsening) response.

Results

A total of 42 eyes (40 patients) across six centers were included. Mean age was 62.38 ± 9.48 years and 62.5% were males. Nineteen eyes were treatment-naïve, while 23 had received prior anti-VEGF therapy. Mean BCVA improved significantly from 0.78 ± 0.41 to 0.59 ± 0.35 logMAR after the first dose (p < 0.001), and from 0.71 ± 0.43 to 0.59 ± 0.57 logMAR following the third dose (p = 0.011). Significant reductions in CMT, SFCT, and NSD height were observed post-treatment; however, PED height did not change significantly. Similar results were seen in both subgroups after the first injection. Complete SRF resolution was achieved in 43% of eyes, with 45.7% showing optimal and 11.4% suboptimal response. One patient developed bilateral anterior uveitis after the third injection, which resolved with topical corticosteroids.

Conclusion

Intravitreal faricimab appears to be a safe and effective option for CSCR-associated CNV, demonstrating anatomical and functional improvements, particularly in cases with unresponsive to prior anti-VEGFs.